

Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Revised March 2025

Page 1 of 21

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
ADHD Agents														
Amphetamine mixed salts	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Atomoxetine	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Dexamfetamine	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Dexmethylphenidate	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Guanfacine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Lisdexamfetamine	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Methylphenidate	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Anaesthetics & Muscle Relaxants														
Alcuronium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bupivacaine	▲	◆	◆	▲	◆	■	◆	■	▲	◆	◆	▲	▲	◆
Cisatracurium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cyclobenzaprine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Desflurane	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dexmedetomidine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Enflurane	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ephedrine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Etidocaine	▲	◆	◆	▲	◆	■	◆	■	▲	◆	◆	▲	▲	◆
Halothane	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Isoflurane	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Ketamine	▲	◆	◆	▲	◆	■	◆	■	▲	◆	◆	▲	▲	◆
Methocarbamol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nitrous oxide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Propofol	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Rocuronium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ropivacaine	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Sevoflurane	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Sufentanil	▲	◆	◆	▲	◆	■	◆	■	▲	◆	◆	▲	▲	◆
Suxamethonium (succinylcholine)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tetracaine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Thiopental	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tizanidine	◆	◆	◆	◆	◆	●	◆	◆	◆	◆	◆	◆	◆	◆
Vecuronium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Analgesics														
Alfentanil	▲	◆	◆	▲	◆	■	◆	■	▲	◆	◆	▲	▲	◆
Aspirin	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Buprenorphine	▲	◆	◆	▲	◆	■	◆	■	▲	◆	◆	▲	▲	◆
Butalbital	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Celecoxib	◆	◆	◆	◆	■	■	■	◆	◆	■	◆	◆	◆	◆
Codeine	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Dexketoprofen	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Dextropropoxyphene	▲	◆	◆	▲	◆	●	◆	●	▲	◆	◆	▲	▲	◆
Diamorphine (diacetylmorphine)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Diclofenac	◆	▲	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Dihydrocodeine	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Etoricoxib	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Fentanyl	▲	◆	◆	▲	◆	■	◆	■	▲	◆	◆	▲	▲	◆
Hydrocodone	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Hydromorphone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ibuprofen	◆	▲	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Indometacin (Indomethacin)	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Ketoprofen	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Ketorolac	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Mefenamic acid	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Meloxicam	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Metamizole	●	●	◆	●	■	■	■	■	●	■	●	●	●	◆
Methodone	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆
Morphine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction which may require dose adjustment or close monitoring
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Check for Updates

Using a saved or printed version? Click or scan to check for updates



Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Revised March 2025

Page 2 of 21

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
Analgesics (continued)														
Nabumetone	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Naproxen	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Nefopam	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Nimesulide	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Oxycodone	▲	◆	◆	▲	◆	■	◆	■	▲	◆	◆	▲	▲	◆
Paracetamol (Acetaminophen)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pethidine (Meperidine)	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Piroxicam	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Remifentanyl	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tapentadol	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Tramadol	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Antiarrhythmics														
Amiodarone	▲	◆	◆	▲	■	●	■	●	▲	■	◆	▲	▲	◆
Bepidil	◆	◆	◆	◆	■	●	■	●	◆	■	◆	◆	◆	◆
Digoxin	◆	◆	◆	◆	■	●	■	●	◆	■	■	◆	◆	◆
Disopyramide	◆	◆	◆	◆	■	●	■	●	◆	■	◆	◆	◆	◆
Dofetilide	◆	◆	◆	◆	■	●	■	●	◆	■	◆	◆	◆	◆
Dronedarone	◆	◆	▲	◆	■	■	■	■	◆	■	■	◆	◆	◆
Flecainide	◆	◆	◆	◆	■	●	■	■	◆	■	◆	◆	◆	◆
Lidocaine (Lignocaine)	◆	◆	◆	◆	■	●	■	◆	◆	■	◆	◆	◆	◆
Mexiletine	◆	◆	◆	◆	■	■	■	▲	◆	■	◆	◆	◆	◆
Propafenone	◆	◆	◆	◆	■	■	■	▲	◆	■	◆	◆	◆	◆
Quinidine	▲	◆	◆	▲	■	●	■	■	▲	■	◆	▲	▲	◆
Antibacterials														
Amikacin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Amoxicillin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ampicillin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Azithromycin	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Bedaquiline	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Capreomycin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cefalexin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cefazolin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cefepime	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cefixime	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cefotaxime	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ceftazidime	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ceftriaxone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cefuroxime	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Chloramphenicol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ciprofloxacin	◆	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Clarithromycin	◆	◆	▲	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Clavulanic acid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clindamycin	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Clofazimine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cloxacillin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cycloserine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dapsone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Delamanid	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Doxycycline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ertapenem	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Erythromycin	◆	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Ethambutol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ethionamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Flucloxacillin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fosfomycin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Furazolidone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fusidic acid (oral or IV)	◆	◆	◆	◆	◆	■	◆	●	◆	◆	●	◆	◆	◆
Fusidic acid (topical)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction which may require dose adjustment or close monitoring
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Check for Updates

Using a saved or printed version? Click or scan to check for updates



Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Revised March 2025

Page 3 of 21

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
Antibacterials (continued)														
Gentamicin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Imipenem/Cilastatin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Isoniazid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Kanamycin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Levofloxacin	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Linezolid	■	■	◆	■	◆	●	◆	◆	■	◆	■	■	■	◆
Lymecycline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Meropenem	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Metronidazole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Minocycline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Moxifloxacin	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Nitrofurantoin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ofloxacin	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Para-aminosalicylic acid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Penicillins	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Piperacillin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pyrazinamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rifabutin	◆	◆	◆	◆	■	■	■	●	◆	■	■	◆	◆	◆
Rifampicin (Rifampin)	◆	◆	◆	◆	■	◆	■	●	◆	■	■	◆	◆	◆
Rifapentine	◆	◆	◆	◆	■	◆	■	●	◆	■	■	◆	◆	◆
Rifaximin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Spectinomycin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Streptomycin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sulfadiazine	◆	◆	◆	◆	◆	▲	◆	■	◆	◆	◆	◆	◆	◆
Tazobactam	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Teicoplanin	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Telavancin	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Telithromycin	◆	◆	▲	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Tetracyclines	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tinidazole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tobramycin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Trimethoprim/Sulfamethoxazole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vancomycin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Anti-coagulant, Anti-platelet and Fibrinolytic														
Acenocoumarol	▲	◆	◆	▲	■	■	■	●	▲	■	◆	▲	▲	◆
Apixaban	▲	◆	◆	▲	■	■	◆	■	▲	■	◆	▲	▲	◆
Argatroban	◆	◆	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	◆	◆
Aspirin (anti-platelet)	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Betrixaban	◆	◆	◆	◆	■	■	◆	◆	◆	■	◆	◆	◆	◆
Cilostazol	■	■	◆	■	◆	●	◆	■	■	◆	■	■	■	◆
Clopidogrel	▲	◆	◆	▲	◆	●	◆	■	▲	◆	◆	▲	▲	◆
Clopidogrel (recently stented patients)	▲	◆	◆	▲	◆	●	◆	●	▲	◆	◆	▲	▲	◆
Dabigatran	◆	◆	◆	◆	■	■	◆	◆	◆	■	■	◆	◆	◆
Dalteparin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dipyridamole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Edoxaban	◆	◆	◆	◆	■	■	◆	◆	◆	■	■	◆	◆	◆
Enoxaparin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fondaparinux	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Heparin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Phenprocoumon	▲	◆	◆	▲	■	■	■	●	▲	■	◆	▲	▲	◆
Prasugrel	▲	◆	◆	▲	◆	◆	◆	◆	▲	◆	◆	▲	▲	◆
Rivaroxaban	▲	◆	◆	▲	■	■	◆	■	▲	■	◆	▲	▲	◆
Streptokinase	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ticagrelor	▲	◆	◆	▲	◆	■	◆	■	▲	◆	▲	▲	▲	◆
Ticlopidine	■	■	◆	■	◆	●	◆	■	■	◆	■	■	■	◆
Tinzaparin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vorapaxar	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	◆
Warfarin	▲	◆	◆	▲	■	■	■	●	▲	■	◆	▲	▲	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction which may require dose adjustment or close monitoring
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Check for Updates

Using a saved or printed version? Click or scan to check for updates



Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Revised March 2025

Page 4 of 21

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
Anticonvulsants														
Brivaracetam	◆	◆	◆	◆	◆	▲	◆	◆	◆	◆	◆	◆	◆	◆
Carbamazepine	▲	◆	◆	▲	■	■	■	●	▲	■	■	▲	▲	◆
Cenobamate	◆	▲	◆	◆	■	▲	■	●	◆	■	■	◆	◆	◆
Clonazepam	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Eslicarbazepine	◆	◆	◆	◆	■	◆	■	●	◆	■	■	◆	◆	◆
Ethosuximide	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Fosphenytoin	▲	◆	◆	▲	■	■	■	●	▲	■	■	▲	▲	◆
Gabapentin	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Lacosamide	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Lamotrigine	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Levetiracetam	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Oxcarbazepine	◆	◆	◆	◆	■	◆	■	●	◆	■	■	◆	◆	◆
Perampanel	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Phenobarbital (Phenobarbitone)	▲	◆	◆	▲	■	■	■	●	▲	■	■	▲	▲	◆
Phenytoin	▲	◆	◆	▲	■	■	■	●	▲	■	■	▲	▲	◆
Pregabalin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Primidone	▲	◆	◆	▲	■	■	■	●	▲	■	■	▲	▲	◆
Retigabine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rufinamide	◆	◆	◆	◆	■	◆	■	◆	◆	■	■	◆	◆	◆
Sodium valproate	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Sultiame	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	▲	◆	◆	◆
Tiagabine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Topiramate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	◆
Valproate semisodium (Divalproex)	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Valproic acid	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Vigabatrin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Zonisamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Antidepressants														
Agomelatine	◆	◆	◆	◆	◆	●	◆	◆	◆	◆	◆	◆	◆	◆
Amitriptyline	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Bupropion	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Citalopram	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Clomipramine	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Desipramine	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Desvenlafaxine	◆	◆	◆	◆	◆	▲	◆	◆	◆	◆	◆	◆	◆	◆
Doxepin	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Duloxetine	◆	◆	◆	◆	◆	●	◆	▲	◆	◆	◆	◆	◆	◆
Escitalopram	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Fluoxetine	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Imipramine	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Lithium	◆	◆	◆	◆	■	■	■	◆	◆	■	◆	◆	◆	◆
Maprotiline	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Mianserin	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Milnacipran	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Mirtazapine	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Moclobemide	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Nefazodone	◆	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Nortriptyline	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Opipramol	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Paroxetine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Phenelzine	◆	◆	◆	◆	◆	●	◆	◆	◆	◆	◆	◆	◆	◆
Reboxetine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Sertraline	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Tranlycypromine	◆	◆	◆	◆	◆	●	◆	◆	◆	◆	◆	◆	◆	◆
Trazodone	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Trimipramine	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Venlafaxine	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Vilazodone	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Vortioxetine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction which may require dose adjustment or close monitoring
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Check for Updates

Using a saved or printed version? Click or scan to check for updates



Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Revised March 2025

Page 5 of 21

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
Anti-diabetics														
Acarbose	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Alogliptin	◆	◆	◆	◆	■	■	■	◆	◆	■	◆	◆	◆	◆
Canagliflozin	◆	◆	◆	◆	■	■	■	◆	◆	■	◆	◆	◆	◆
Dapagliflozin	◆	◆	◆	◆	■	■	■	◆	◆	■	◆	◆	◆	◆
Dulaglutide	◆	◆	◆	◆	■	■	■	◆	◆	■	◆	◆	◆	◆
Empagliflozin	◆	◆	◆	◆	■	■	■	◆	◆	■	■	◆	◆	◆
Exenatide	◆	◆	◆	◆	■	■	■	◆	◆	■	◆	◆	◆	◆
Glibenclamide (Glyburide)	◆	◆	◆	◆	■	■	■	■	◆	■	◆	◆	◆	◆
Gliclazide	◆	◆	◆	◆	■	■	■	■	◆	■	◆	◆	◆	◆
Glimepiride	◆	◆	◆	◆	■	■	■	■	◆	■	◆	◆	◆	◆
Glipizide	◆	◆	◆	◆	■	■	■	■	◆	■	◆	◆	◆	◆
Insulin	◆	◆	◆	◆	■	■	■	◆	◆	■	◆	◆	◆	◆
Linagliptin	◆	◆	◆	◆	■	■	■	◆	◆	■	◆	◆	◆	◆
Liraglutide	◆	◆	◆	◆	■	■	■	◆	◆	■	◆	◆	◆	◆
Metformin	◆	◆	◆	◆	■	■	■	◆	◆	■	◆	◆	◆	◆
Nateglinide	◆	◆	◆	◆	■	■	■	■	◆	■	◆	◆	◆	◆
Pioglitazone	◆	◆	◆	◆	■	■	■	◆	◆	■	◆	◆	◆	◆
Repaglinide	◆	◆	◆	◆	■	■	■	■	◆	■	◆	◆	◆	◆
Rosiglitazone	◆	◆	◆	◆	■	■	■	■	◆	■	◆	◆	◆	◆
Saxagliptin	◆	◆	◆	◆	■	■	■	■	◆	■	◆	◆	◆	◆
Semaglutide	◆	◆	◆	◆	■	■	■	◆	◆	■	◆	◆	◆	◆
Sitagliptin	◆	◆	◆	◆	■	■	■	◆	◆	■	◆	◆	◆	◆
Tirzepatide	◆	◆	◆	◆	■	■	■	◆	◆	■	◆	◆	◆	◆
Tolbutamide	◆	◆	◆	◆	■	■	■	■	◆	■	◆	◆	◆	◆
Vildagliptin	◆	◆	◆	◆	■	■	■	◆	◆	■	◆	◆	◆	◆
Antifungals														
Amphotericin B	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Anidulafungin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Caspofungin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clotrimazole (pessary, troche)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	◆
Clotrimazole (topical)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fluconazole	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	■	◆	◆	◆
Flucytosine	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆
Griseofulvin	◆	◆	◆	◆	■	■	■	■	◆	■	◆	◆	◆	◆
Isavuconazole	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	■	◆	◆	◆
Itraconazole	◆	◆	▲	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Ketoconazole	◆	◆	▲	◆	◆	■	◆	◆	◆	◆	■	◆	◆	◆
Micafungin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Miconazole	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	■	◆	◆	◆
Nystatin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Posaconazole	◆	◆	▲	◆	◆	◆	◆	■	◆	◆	■	◆	◆	◆
Rezafungin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Terbinafine	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Voriconazole	◆	◆	▲	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Antithrombotics														
Avatrombopag	◆	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Eltrombopag	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Emicizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fostamatinib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Tranexamic acid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction which may require dose adjustment or close monitoring
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Check for Updates

Using a saved or printed version? Click or scan to check for updates



Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Revised March 2025

Page 6 of 21

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
Antihistamines														
Azelastine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bilastine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	◆
Cetirizine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Chlorphenamine	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Desloratadine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Diphenhydramine	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Doxylamine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Fexofenadine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Levocetirizine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Loratadine	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Meclizine	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Promethazine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Antimalarials														
Amodiaquine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Artemether	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Artesunate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Atovaquone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Chloroquine	■	■	◆	■	■	■	■	■	■	■	■	■	■	◆
Halofantrine	◆	◆	◆	◆	◆	●	◆	●	◆	◆	◆	▲	▲	◆
Hydroxychloroquine	■	■	◆	■	■	■	■	■	■	■	■	■	■	◆
Lumefantrine	◆	◆	◆	◆	◆	●	◆	■	◆	◆	◆	◆	◆	◆
Mefloquine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Piperaquine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Primaquine	■	■	◆	■	◆	■	◆	◆	■	◆	■	■	■	◆
Proguanil	◆	◆	◆	◆	◆	▲	◆	■	◆	◆	◆	◆	◆	◆
Pyrimethamine	■	■	◆	■	◆	▲	◆	◆	■	◆	■	■	■	◆
Quinine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Sulfadoxine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Antimigraine Agents														
Almotriptan	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Atogepant	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dihydroergotamine	◆	◆	◆	◆	◆	●	◆	●	◆	◆	■	◆	◆	◆
Eletriptan	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Eptinezumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Erenumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ergotamine	◆	◆	◆	◆	◆	●	◆	●	◆	◆	◆	◆	◆	◆
Fremanuzemab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Frovatriptan	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Galcanezumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Naratriptan	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Pizotifen	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rimegepant	◆	◆	◆	◆	◆	■	◆	■	◆	◆	●	◆	◆	◆
Rizatriptan	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Sumatriptan	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Ubrogepant	◆	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Zolmitriptan	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	■	◆	◆	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction which may require dose adjustment or close monitoring
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Check for Updates

Using a saved or printed version? Click or scan to check for updates



Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Revised March 2025

Page 7 of 21

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
Antipsychotics/Neuroleptics														
Amisulpride	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Aripiprazole	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Asenapine	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Brexpiprazole	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Cariprazine	■	■	◆	■	◆	●	◆	●	■	◆	■	■	■	◆
Chlorpromazine	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Clozapine	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Flupentixol (Flupenthixol)	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Fluphenazine	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Haloperidol	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Iloperidone	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Levomepromazine	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Lumateperone	■	■	◆	■	◆	●	◆	●	■	◆	■	■	■	◆
Lurasidone	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Olanzapine	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Paliperidone	◆	◆	◆	◆	◆	▲	◆	◆	◆	◆	◆	◆	◆	◆
Perazine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Periciazine	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Perphenazine	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Pimavanserin	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Pimozide	◆	◆	◆	◆	◆	●	◆	●	◆	◆	◆	◆	◆	◆
Pipotiazine	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Quetiapine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Risperidone	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Sulpiride	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Thioridazine	◆	◆	◆	◆	■	●	■	●	◆	■	■	◆	◆	◆
Tiapride	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Ziprasidone	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Zotepine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Zuclopenthixol	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Antivirals														
Aciclovir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Adefovir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Baloxavir	◆	▲	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Brincidofovir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bulevirtide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cidofovir	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆
Entecavir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Famciclovir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Foscarnet	◆	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Ganciclovir	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Letermovir	◆	▲	◆	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	◆
Maribavir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Oseltamivir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ribavirin	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Rimantadine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tecovirimat	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Telbivudine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tenofovir alafenamide (HBV)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Valaciclovir (Valacyclovir)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Valganciclovir	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Zanamivir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction which may require dose adjustment or close monitoring
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Check for Updates

Using a saved or printed version? Click or scan to check for updates



Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Revised March 2025

Page 8 of 21

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
Anxiolytics/Hypnotics/Sedatives														
Alprazolam	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Bromazepam	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Buspirone	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Chlordiazepoxide	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Clobazam	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Clorazepate	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Diazepam	◆	◆	◆	◆	◆	●	◆	■	◆	◆	◆	◆	◆	◆
Estazolam	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Eszopiclone	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Flunitrazepam	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Flurazepam	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Hydroxyzine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Lorazepam	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lormetazepam	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Midazolam (buccal)	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Midazolam (oral)	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Midazolam (parenteral)	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Oxazepam	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Suvorexant	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Temazepam	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Triazolam	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Zaleplon	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Zolpidem	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Zopiclone	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Benign Prostatic Hyperplasia Therapies														
Alfuzosin	◆	◆	◆	◆	◆	●	◆	●	◆	◆	◆	◆	◆	◆
Dutasteride	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Finasteride (5 mg)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Silodosin	◆	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Tadalafil (BPH)	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Tamsulosin	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Beta Blockers														
Atenolol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bisoprolol	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Carvedilol	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Metoprolol	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Nebivolol	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Oxprenolol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Propranolol	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Pindolol	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Sotalol	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Timolol	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Bisphosphonates														
Alendronic acid (Alendronate)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ibandronic acid (Ibandronate)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Risedronic acid (Risedronate)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Zoledronic acid (Zoledronate)	◆	◆	◆	◆	◆	◆	◆	■	■	◆	■	◆	◆	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction which may require dose adjustment or close monitoring
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Check for Updates

Using a saved or printed version? Click or scan to check for updates



Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Revised March 2025

Page 9 of 21

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
Bronchodilators														
Acclidinium bromide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Aminophylline	▲	◆	◆	▲	◆	■	◆	◆	▲	◆	◆	▲	▲	◆
Formoterol	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Glycopyrronium bromide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Indacaterol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ipratropium bromide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Montelukast	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Olodaterol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Roflumilast	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Salbutamol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Salmeterol	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Terbutaline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Theophylline	▲	◆	◆	▲	◆	■	◆	◆	▲	◆	◆	▲	▲	◆
Tiotropium bromide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Umeclidinium bromide	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Vilanterol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Calcium Channel Blockers														
Amlodipine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Diltiazem	◆	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Felodipine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Nicardipine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Nifedipine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Nisoldipine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Nitrendipine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Verapamil	◆	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Cancer Therapies														
Abemaciclib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Abiraterone	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Acalabrutinib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Afatinib	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Aldesleukin	■	■	◆	■	■	◆	■	■	■	■	■	■	■	◆
Alectinib	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Alpelisib	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Amivantamab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Anastrozole	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Apalutamide	◆	◆	◆	◆	■	◆	■	●	◆	■	■	◆	◆	◆
Asciminib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Atezolizumab	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Avapritinib	■	■	◆	■	▲	●	▲	●	■	▲	■	■	■	◆
Avelumab	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Axitinib	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Azacitidine	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Bendamustine	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Bevacizumab	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Bexarotene	◆	◆	◆	◆	■	◆	■	●	◆	■	■	◆	◆	◆
Bicalutamide	◆	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Binimetinib	◆	▲	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Blinatumomab	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Bortezomib	■	■	◆	■	◆	▲	◆	■	■	◆	■	■	■	◆
Bosutinib	■	■	◆	■	◆	●	◆	●	■	◆	■	■	■	◆
Brentuximab vedotin	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Brigatinib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Busulfan	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction which may require dose adjustment or close monitoring
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Check for Updates

Using a saved or printed version? Click or scan to check for updates



Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Revised March 2025

Page 10 of 21

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
Cancer Therapies (continued)														
Cabazitaxel	■	■	◆	■	◆	▲	◆	■	■	◆	■	■	■	◆
Cabozantinib	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Capecitabine	■	■	◆	■	◆	◆	◆	◆	■	◆	■	■	■	◆
Capmatinib	◆	▲	◆	◆	◆	◆	◆	▲	◆	◆	◆	◆	◆	◆
Carboplatin	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Carfilzomib	■	■	◆	■	◆	◆	◆	◆	■	◆	■	■	■	◆
Cedazuridine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cemiplimab	◆	◆	◆	◆	◆	◆	◆	■	■	◆	■	◆	◆	◆
Ceritinib	◆	◆	▲	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Cetuximab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Chlorambucil	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Cobimetinib	◆	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Copanlisib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Crizotinib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Cyclophosphamide	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Dabrafenib	■	■	◆	■	■	■	■	●	■	■	■	■	■	◆
Dacarbazine	■	■	◆	■	◆	●	◆	■	■	◆	■	■	■	◆
Dacomitinib	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Dactinomycin	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Daratumumab	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Darolutamide	◆	■	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dasatinib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Decitabine	■	■	◆	■	◆	◆	◆	■	■	◆	◆	■	■	◆
Docetaxel	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Doxorubicin	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Durvalumab	■	■	◆	■	■	◆	■	■	■	■	■	■	■	◆
Duvelisib	■	■	▲	■	◆	■	◆	■	■	◆	■	■	■	◆
Elotuzumab	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Enasidenib	◆	▲	◆	◆	■	■	■	●	◆	■	■	◆	◆	◆
Encorafenib	◆	◆	◆	◆	◆	■	◆	■	■	◆	◆	◆	◆	◆
Enfortumab vedotin	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Entrectinib	■	■	◆	■	◆	●	◆	●	■	◆	■	■	■	◆
Enzalutamide	◆	◆	◆	◆	■	■	■	●	◆	■	■	◆	◆	◆
Epcoritamab	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Epirubicin	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Erdafitinib	◆	◆	◆	◆	◆	■	◆	■	■	◆	■	■	■	◆
Eribulin	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Erlotinib	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Etoposide	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Exemestane	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fedratinib	■	●	▲	■	◆	▲	◆	■	■	◆	●	■	■	◆
Fluorouracil (5-FU)	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Flutamide	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Fulvestrant	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Gefitinib	◆	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Gemcitabine	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Gilteritinib	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	■	◆	◆	◆
Glasdegib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Hydroxycarbamide (Hydroxyurea)	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Ibrutinib	■	■	◆	■	◆	▲	◆	■	■	◆	■	■	■	◆
Idarubicin	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Idelalisib	■	■	▲	■	◆	◆	◆	■	■	◆	■	■	■	◆
Imatinib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Infigratinib	■	■	◆	■	◆	●	◆	●	■	◆	■	■	■	◆
Inotuzumab ozogamicin	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Ipilimumab	■	■	◆	■	■	◆	■	■	■	■	■	■	■	◆
Irinotecan	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Isatuximab	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Isotretinoin	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Ivosidenib	◆	◆	◆	◆	■	■	■	●	◆	■	■	◆	◆	◆
Ixazomib	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction which may require dose adjustment or close monitoring
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Check for Updates

Using a saved or printed version? Click or scan to check for updates



Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Revised March 2025

Page 11 of 21

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
Cancer Therapies (continued)														
Lapatinib	◆	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Larotrectinib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Lenalidomide	■	■	◆	■	◆	◆	◆	◆	■	◆	■	■	■	◆
Lenvatinib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Letrozole	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Lomustine	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Lorlatinib	■	■	◆	■	■	■	■	●	◆	■	■	■	■	◆
Mercaptopurine	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Methotrexate	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Midostaurin	■	■	◆	■	◆	■	◆	■	◆	◆	■	■	■	◆
Mitomycin	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Mitotane	■	■	◆	■	■	◆	■	●	■	■	■	■	■	◆
Mobocertinib	■	■	◆	■	◆	●	◆	●	■	◆	■	■	■	◆
Necitumumab	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Neratinib	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆
Nilotinib	■	■	◆	■	◆	■	◆	◆	■	◆	■	■	■	◆
Niraparib	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Nivolumab	■	■	◆	■	■	◆	■	■	■	■	■	■	■	◆
Obinutuzumab	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Ofatumumab	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Olaparib	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Olaratumab	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Osimertinib	■	■	◆	■	◆	■	◆	◆	■	◆	■	■	■	◆
Oxaliplatin	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Paclitaxel	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Palbociclib	■	■	◆	■	◆	▲	◆	▲	■	◆	■	■	■	◆
Panitumumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Panobinostat	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Pazopanib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Pembrolizumab	■	■	◆	■	■	◆	■	■	■	■	■	■	■	◆
Pemetrexed	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Pemigatinib	■	■	◆	■	◆	●	◆	●	■	◆	■	■	■	◆
Pertuzumab	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Pexidartinib	■	■	◆	■	■	●	■	●	■	■	■	■	■	◆
Polatuzumab vedotin	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Pomalidomide	■	■	◆	■	◆	■	◆	◆	■	◆	■	■	■	◆
Ponatinib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Pralsetinib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Regorafenib	■	■	◆	■	◆	●	◆	●	■	◆	■	■	■	◆
Relugolix	◆	◆	◆	◆	◆	▲	◆	■	◆	◆	◆	◆	◆	◆
Repotrectinib	◆	◆	◆	◆	◆	●	◆	●	◆	◆	■	◆	◆	◆
Ribociclib	■	■	▲	■	◆	◆	◆	■	■	◆	■	■	■	◆
Ripretinib	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Rituximab	●	●	◆	●	◆	◆	◆	■	●	◆	●	●	●	◆
Romidepsin	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Rucaparib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Selinexor	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Selpercatinib	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Sonidegib	■	■	◆	■	◆	●	◆	●	■	◆	■	■	■	◆
Sorafenib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Sotorasib	◆	◆	◆	◆	■	◆	■	●	◆	■	■	◆	◆	◆
Sunitinib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction which may require dose adjustment or close monitoring
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Check for Updates

Using a saved or printed version? Click or scan to check for updates



Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Revised March 2025

Page 12 of 21

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
Cancer Therapies (continued)														
Talazoparib	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Tamoxifen	◆	◆	◆	◆	■	■	■	■	◆	■	■	◆	◆	◆
Tegafur/ Gimeracil/ Oteracil	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Temsirolimus	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Tepotinib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Thalidomide	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Thiotepa	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Tisotumab vedotin	■	■	■	■	◆	■	◆	■	■	◆	■	■	■	◆
Tivozanib	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Topotecan	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Toremifene	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Trametinib	◆	▲	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆
Trastuzumab	■	■	◆	■	◆	▲	◆	■	■	◆	■	■	■	◆
Trastuzumab emtansine	■	■	◆	■	◆	▲	◆	■	■	◆	■	■	■	◆
Trifluridine/Tipiracil	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Umbralisib	■	■	◆	■	■	●	■	●	■	■	■	■	■	◆
Vandetanib	■	■	◆	■	◆	●	◆	●	■	◆	■	■	■	◆
Vemurafenib	■	■	◆	■	■	■	■	●	■	■	■	■	■	◆
Venetoclax	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Vinblastine	■	■	◆	■	▲	■	▲	■	■	▲	■	■	■	◆
Vincristine	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Vinorelbine	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Zanubrutinib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Contraceptives/HRT														
Conjugated estrogens (HRT)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Desogestrel (COC)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Desogestrel (POP)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Drospirenone (COC)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Drospirenone (HRT)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dydrogesterone (HRT)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Estradiol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ethinylestradiol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Etonogestrel (implant)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Etonogestrel (vaginal ring)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Gestodene (COC)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Levonorgestrel (COC)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Levonorgestrel (emergency contraception)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Levonorgestrel (HRT)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Levonorgestrel (implant)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Levonorgestrel (IUD)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Levonorgestrel (POP)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Medroxyprogesterone (depot injection)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Medroxyprogesterone (oral)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Norelgestromin (patch)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Norethisterone (COC)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Norethisterone (HRT)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Norethisterone (IM depot)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Norethisterone (POP)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Norgestimate (COC)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Norgestrel (COC)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Norgestrel (HRT)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Progesterone (HRT)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ulipristal	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction which may require dose adjustment or close monitoring
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Check for Updates

Using a saved or printed version? Click or scan to check for updates



Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Revised March 2025

Page 13 of 21

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
Cough and Cold Preparations														
Benzonatate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Carbocisteine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dextromethorphan	◆	◆	◆	◆	◆	▲	◆	◆	◆	◆	◆	◆	◆	◆
Guaifenesin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pseudoephedrine	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Covid-19 Antiviral Therapies														
Casirivimab/Imdevimab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ensitrelvir	◆	◆	▲	◆	▲	◆	▲	■	◆	▲	■	◆	◆	◆
Favipiravir	◆	▲	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Molnupiravir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Niclosamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nirmatrelvir + ritonavir (5 day)	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	■	◆	◆	◆
Nirmatrelvir + ritonavir (≥ 10 days)	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	■	◆	◆	◆
Nitazoxanide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Remdesivir	◆	◆	◆	◆	◆	◆	◆	▲	◆	◆	◆	◆	◆	◆
Sotrovimab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tixagevimab/Cilgavimab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Covid-19 Host-directed Therapies														
Anakinra	◆	●	◆	●	◆	◆	◆	■	●	◆	●	●	●	◆
Baricitinib	●	◆	◆	●	◆	◆	◆	■	●	◆	●	●	●	◆
Budesonide (inhaled)	◆	◆	◆	◆	◆	▲	◆	◆	◆	◆	◆	◆	◆	◆
Canakinumab	●	●	◆	◆	◆	◆	◆	■	●	◆	●	●	●	◆
Covid 19 convalescent plasma	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Covid-19 vaccines	◆	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆
Dexamethasone (low dose; ≤16 mg)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fluvoxamine	◆	◆	▲	◆	◆	◆	◆	▲	◆	◆	■	◆	◆	◆
Hydrocortisone (oral or IV)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Imatinib (14 days)	■	■	◆	■	◆	▲	◆	◆	■	◆	■	■	■	◆
Infliximab	●	●	◆	●	◆	◆	◆	■	◆	◆	●	●	●	◆
Methylprednisolone (oral or IV)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ruxolitinib	●	●	◆	●	◆	■	◆	■	●	◆	◆	●	●	◆
Sarilumab	●	●	◆	●	◆	◆	◆	■	●	◆	●	◆	●	◆
Tocilizumab	●	●	◆	●	◆	◆	◆	■	●	◆	●	●	◆	◆
Vilobelimab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cystic Fibrosis Agents														
Ivacaftor	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Ivacaftor/lumacaftor	◆	▲	◆	◆	■	◆	■	●	◆	■	■	◆	◆	◆
Ivacaftor/tezacaftor	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Ivacaftor/tezacaftor/elexacaftor	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Dementia Therapies														
Donepezil	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Galantamine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Memantine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rivastigmine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Erectile Dysfunction Agents														
Alprostadil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Avanafil	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Sildenafil (erectile dysfunction)	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Tadalafil (erectile dysfunction)	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Vardenafil	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction which may require dose adjustment or close monitoring
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Check for Updates

Using a saved or printed version? Click or scan to check for updates



Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Revised March 2025

Page 14 of 21

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
Gastrointestinal Agents														
Alosetron	◆	◆	◆	◆	◆	●	◆	◆	◆	◆	◆	◆	◆	◆
Antacids	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Bisacodyl	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Bismuth subsalicylate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cimetidine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	▲	◆	◆	◆
Cisapride	◆	◆	◆	◆	◆	●	◆	●	◆	◆	◆	◆	◆	◆
Dexlansoprazole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dicycloverine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Docusate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Esomeprazole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Famotidine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Hyoscine butylbromide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ispaghula husk	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lactulose	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Lansoprazole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Linaclotide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Loperamide	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Macrogol (Polyethylene Glycol 3350)	◆	▲	◆	◆	▲	▲	▲	▲	◆	▲	▲	◆	◆	◆
Magnesium salts (oral)	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Mebeverine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mesalazine (mesalamine)	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Naloxegol	◆	◆	◆	◆	◆	■	◆	■	◆	◆	▲	◆	◆	◆
Nizatidine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Octreotide	◆	◆	◆	◆	◆	■	▲	■	◆	▲	▲	◆	◆	◆
Omeprazole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pantoprazole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Prucalopride	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Psyllium husk	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rabeprazole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ranitidine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	▲	◆	◆	◆
Senna	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Sucralfate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Gastrointestinal Agents (anti-emetics)														
Aprepitant	◆	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Cyclizine	◆	◆	◆	◆	◆	▲	◆	◆	◆	◆	◆	◆	◆	◆
Dolasetron	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Domperidone	◆	◆	◆	◆	◆	●	◆	●	◆	◆	◆	◆	◆	◆
Dronabinol	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Fosaprepitant	◆	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Granisetron	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Hyoscine (Scopolamine)	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Hyoscine hydrobromide	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Metoclopramide	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Netupitant	◆	◆	◆	◆	▲	■	◆	■	◆	◆	■	◆	◆	◆
Ondansetron	◆	■	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Palonosetron	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Prochlorperazine	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Rolapitant	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction which may require dose adjustment or close monitoring
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Check for Updates

Using a saved or printed version? Click or scan to check for updates



Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Revised March 2025

Page 15 of 21

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
HCV DAAs														
Elbasvir/Grazoprevir	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	▲	◆	◆	◆
Glecaprevir/Pibrentasvir	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	▲	◆	◆	◆
Ledipasvir/Sofosbuvir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	▲	◆	◆	◆
Ombitasvir/Paritaprevir/r	◆	◆	▲	◆	◆	◆	◆	■	◆	◆	■	◆	◆	◆
Ombitasvir/Paritaprevir/r + Dasabuvir	◆	◆	▲	◆	◆	◆	◆	■	◆	◆	■	◆	◆	◆
Sofosbuvir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sofosbuvir/Velpatasvir	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆
Sofosbuvir/Velpatasvir/Voxilaprevir	◆	◆	◆	◆	◆	◆	◆	●	◆	◆	◆	◆	◆	◆
HIV Antiretroviral Therapies														
Abacavir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Albuvirtide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Atazanavir alone	◆	◆	▲	◆	◆	◆	◆	■	◆	◆	■	◆	◆	◆
Atazanavir + ritonavir	◆	◆	▲	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Atazanavir/cobicistat	◆	◆	▲	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Bictegravir/Emtricitabine/TAF	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cabotegravir (oral)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cabotegravir/rilpivirine (long acting)	◆	◆	◆	◆	■	■	◆	■	◆	◆	◆	◆	◆	◆
Darunavir + ritonavir	◆	◆	▲	◆	◆	▲	◆	■	◆	◆	■	◆	◆	◆
Darunavir/cobicistat	◆	◆	▲	◆	◆	▲	◆	■	◆	◆	■	◆	◆	◆
Darunavir/Cobi/Emtricitabine/TAF	◆	◆	▲	◆	◆	▲	◆	■	◆	◆	■	◆	◆	◆
Dolutegravir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dolutegravir/Lamivudine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dolutegravir/Rilpivirine	◆	◆	◆	◆	■	■	◆	■	◆	◆	◆	◆	◆	◆
Dolutegravir/Abacavir/Lamivudine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Doravirine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Doravirine/Lamivudine/Tenofovir-DF	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Efavirenz	◆	◆	◆	◆	■	◆	■	●	◆	■	■	◆	◆	◆
Elvitegravir/Cobi/Emtricitabine/TAF	◆	◆	▲	◆	◆	▲	◆	■	◆	◆	■	◆	◆	◆
Elvitegravir/Cobi/Emtricitabine/TDF	◆	◆	▲	◆	◆	▲	◆	■	◆	◆	■	◆	◆	◆
Emtricitabine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Emtricitabine/Tenofovir alafenamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Emtricitabine/Tenofovir-DF	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Etravirine	◆	◆	◆	◆	■	▲	■	●	◆	■	■	◆	◆	◆
Fostemsavir	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Ibalizumab-uiyk	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lamivudine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lenacapavir	◆	◆	◆	◆	◆	◆	◆	▲	◆	◆	■	◆	◆	◆
Lopinavir/ritonavir	◆	◆	▲	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Maraviroc	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Nevirapine	◆	◆	◆	◆	■	▲	■	●	◆	■	■	◆	◆	◆
Raltegravir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rilpivirine	◆	◆	◆	◆	■	■	◆	■	◆	◆	◆	◆	◆	◆
Rilpivirine/Emtricitabine/TAF	◆	◆	◆	◆	■	■	◆	■	◆	◆	◆	◆	◆	◆
Rilpivirine/Emtricitabine/TDF	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆	◆	◆	◆
Tenofovir-DF	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Zidovudine	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction which may require dose adjustment or close monitoring
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Check for Updates

Using a saved or printed version? Click or scan to check for updates



Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Revised March 2025

Page 17 of 21

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
Illicit/Recreational														
Alcohol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Amphetamine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Cannabis (Marijuana)	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Carfentanil	◆	◆	◆	◆	◆	●	◆	●	◆	◆	◆	◆	◆	◆
Cocaine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ecstasy (MDMA)	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Enobosarm (Ostarine)	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
GHB (Gamma-hydroxybutyrate)	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Heroin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
LSD (Lysergic acid diethylamide)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Methamphetamine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Nitazenes	◆	◆	◆	◆	◆	●	◆	●	◆	◆	▲	◆	◆	◆
Poppers (Amyl nitrate)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Psilocybin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Trenbolone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Immunosuppressants														
Abatacept	●	●	◆	●	◆	◆	◆	■	●	◆	●	●	●	◆
Abrocitinib	●	●	◆	●	◆	■	◆	■	●	◆	●	●	●	◆
Adalimumab	●	●	◆	●	◆	◆	◆	■	●	◆	●	●	●	◆
Anti-thymocyte globulin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Apremilast	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Azathioprine	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Basiliximab	●	●	◆	●	◆	◆	◆	◆	●	◆	●	●	●	◆
Belatacept	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Belimumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bimekizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	◆
Certolizumab pegol	●	●	◆	●	◆	◆	◆	■	●	◆	●	●	●	◆
Ciclosporin	▲	■	◆	▲	■	■	◆	■	▲	◆	■	▲	▲	◆
Dimethyl fumarate	◆	■	◆	■	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Etanercept	●	●	◆	●	◆	◆	◆	◆	●	◆	●	●	●	◆
Everolimus	◆	◆	◆	◆	▲	■	◆	■	◆	◆	◆	◆	◆	◆
Filgotinib	●	●	◆	●	◆	◆	◆	◆	●	◆	●	●	●	◆
Golimumab	●	■	◆	●	◆	◆	◆	■	●	◆	■	●	●	◆
Ixekizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Leflunomide	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Methotrexate	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Mycophenolate	◆	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆
Pirfenidone	◆	◆	◆	◆	◆	●	◆	◆	◆	◆	◆	◆	◆	◆
Risankizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Secukinumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sirolimus	▲	◆	◆	▲	■	■	◆	■	▲	◆	■	▲	▲	◆
Tacrolimus	▲	■	◆	▲	■	■	◆	■	▲	◆	■	▲	▲	◆
Tildrakizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	◆
Tofacitinib	●	●	◆	●	◆	■	◆	■	●	◆	●	●	●	◆
Upadacitinib	●	●	◆	●	◆	■	◆	■	●	◆	●	●	●	◆
Ustekinumab	■	■	◆	■	◆	◆	◆	◆	■	◆	■	■	■	◆
Vedolizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Voclosporin	◆	■	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Inotropes & Vasopressors														
Adrenaline (Epinephrine)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Desmopressin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dobutamine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Noradrenaline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vasopressin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction which may require dose adjustment or close monitoring
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Check for Updates

Using a saved or printed version? Click or scan to check for updates



Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Revised March 2025

Page 18 of 21

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
Lipid Lowering Agents														
Alirocumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Atorvastatin	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Bempedoic acid	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Bezafibrate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clofibrate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Colesevelam	◆	▲	◆	◆	▲	▲	▲	▲	◆	▲	◆	◆	◆	◆
Colestyramine (Cholestyramine)	◆	▲	◆	◆	▲	▲	▲	▲	◆	▲	◆	◆	◆	◆
Evolocumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ezetimibe	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fenofibrate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fish oils	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fluvastatin	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Gemfibrozil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Icosapent ethyl	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Inclisiran	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lomitapide	◆	◆	◆	◆	◆	●	◆	●	◆	◆	◆	◆	◆	◆
Lovastatin	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Pitavastatin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Omega-3 fatty acids	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pravastatin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rosuvastatin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	◆
Simvastatin	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Multiple Sclerosis Agents														
Alemtuzumab	■	■	◆	■	◆	◆	◆	◆	■	◆	■	■	■	◆
Baclofen	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cladribine	■	■	◆	■	◆	◆	◆	◆	■	◆	■	■	■	◆
Dantrolene sodium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fampridine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fingolimod	■	■	◆	■	◆	◆	◆	◆	■	◆	■	■	■	◆
Glatiramer acetate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Natalizumab	■	■	◆	■	◆	◆	◆	◆	■	◆	■	■	■	◆
Ocrelizumab	■	■	◆	■	◆	◆	◆	◆	■	◆	■	■	■	◆
Ozanimod	■	■	◆	■	◆	■	◆	◆	■	◆	■	■	■	◆
Peginterferon beta-1a	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Siponimod	■	■	◆	■	■	●	■	●	■	■	■	■	■	◆
Teriflunomide	■	■	◆	■	◆	◆	◆	◆	■	◆	■	■	■	◆
Ophthalmological Agents														
Brimonidine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Brinzolamide	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Brolucizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Latanoprost	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ranibizumab	◆	◆	◆	◆	◆	◆	◆	■	■	◆	■	◆	◆	◆
Travoprost	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Other														
Acetazolamide	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Acetylcysteine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Acitretin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Activated charcoal	◆	▲	◆	◆	▲	▲	▲	▲	◆	▲	▲	◆	◆	◆
Allopurinol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Atropine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Benralizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Betahistine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bromocriptine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Cannabidiol	◆	◆	◆	◆	◆	■	◆	■	◆	◆	▲	◆	◆	◆
Carbimazole	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Cinacalcet	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Clomifene	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Colchicine	◆	◆	◆	◆	▲	■	◆	■	◆	◆	■	◆	◆	◆
Crizanlizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cytisine (Cytisinicline)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction which may require dose adjustment or close monitoring
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Check for Updates

Using a saved or printed version? Click or scan to check for updates



Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Revised March 2025

Page 19 of 21

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
Other (continued)														
Deferasirox	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Denosumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Disulfiram	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Drotaverine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dupilumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Elagolix	◆	◆	◆	◆	■	■	■	■	◆	■	■	◆	◆	◆
Ergometrine (Ergonovine)	◆	◆	◆	◆	◆	●	◆	●	◆	◆	◆	◆	◆	◆
Febuxostat	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fezolinetant	◆	◆	◆	◆	◆	●	◆	▲	◆	◆	◆	◆	◆	◆
Filgrastim	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Finasteride (1mg)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Flibanserin	◆	◆	◆	◆	◆	●	◆	●	◆	◆	◆	◆	◆	◆
Goserelin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Interferon beta	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Isosorbide mononitrate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ivermectin	◆	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Leuprorelin	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Levothyroxine	◆	◆	◆	◆	▲	◆	▲	■	◆	▲	◆	◆	◆	◆
Liothyronine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Magnesium sulfate (IV)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Melatonin	◆	◆	◆	◆	◆	●	◆	◆	◆	◆	◆	◆	◆	◆
Mepolizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Methimazole	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Methylergometrine	◆	◆	◆	◆	◆	●	◆	●	◆	◆	◆	◆	◆	◆
Misoprostol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Modafinil	◆	◆	◆	◆	■	◆	■	◆	◆	■	■	◆	◆	◆
Naftidrofuryl	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Naloxone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Naltrexone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Neostigmine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nicotine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nintedanib	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	◆
Omalizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Orlistat	◆	▲	◆	◆	▲	▲	▲	▲	◆	▲	▲	◆	◆	◆
Ospemifene	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Pancreatic enzymes (Creon)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pentosan polysulfate sodium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pentoxifylline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Phentermine	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Phenylephrine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pilocarpine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pitolisant	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Potassium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Probenecid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Propylthiouracil	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Pyridostigmine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Raloxifene	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ramelteon	◆	◆	◆	◆	◆	●	◆	■	◆	◆	◆	◆	◆	◆
Riluzole	■	■	◆	■	◆	■	◆	◆	■	◆	■	■	■	◆
Sevelamer	◆	▲	◆	◆	▲	▲	▲	▲	◆	▲	▲	◆	◆	◆
Sodium zirconium cyclosilicate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sulfasalazine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	◆
Tasimelteon	◆	◆	◆	◆	◆	●	◆	■	◆	◆	◆	◆	◆	◆
Telotristat	◆	◆	◆	◆	■	◆	■	●	◆	■	■	◆	◆	◆
Tenapanor	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tolvaptan	◆	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Triclabendazole	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Triptorelin	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Ursodeoxycholic acid (Ursodiol)	◆	◆	◆	◆	■	◆	■	●	◆	■	■	◆	◆	◆
Varenicline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction which may require dose adjustment or close monitoring
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Check for Updates

Using a saved or printed version? Click or scan to check for updates



Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Revised March 2025

Page 20 of 21

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
Overactive Bladder Agents														
Darifenacin	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Fesoterodine	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Mirabegron	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Oxybutynin	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Solifenacin	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Tolterodine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Trospium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Parkinsonism Agents														
Amantadine	◆	◆	◆	◆	◆	▲	◆	◆	◆	◆	◆	◆	◆	◆
Apomorphine	◆	◆	◆	◆	◆	◆	◆	▲	◆	◆	◆	◆	◆	◆
Benserazide/levodopa	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Benzatropine (BENZOTROPINE)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Biperiden	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cabergoline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	▲	◆	◆	◆
Carbidopa	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Carbidopa/levodopa	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Entacapone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Levodopa	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Orphenadrine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	▲	◆	◆	◆
Piribedil	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Pramipexole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Procyclidine	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Rasagiline	◆	◆	◆	◆	◆	●	◆	◆	◆	◆	◆	◆	◆	◆
Ropinirole	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Rotigotine	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Safinamide	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Selegiline	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Steroids														
Beclometasone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Betamethasone	◆	◆	◆	◆	■	▲	■	▲	◆	■	■	◆	◆	◆
Betamethasone (topical)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Budesonide (oral/rectal)	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Ciclesonide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clobetasol	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Deflazacort	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Dexamethasone (>16 mg)	◆	◆	◆	◆	◆	▲	■	■	◆	■	■	◆	◆	◆
Difluprednate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fludrocortisone	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Flunisolide	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Fluocinolone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fluticasone	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Hydrocortisone (topical)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Megestrol acetate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Methylprednisolone (topical)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mometasone	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Nandrolone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Oxandrolone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Oxymetholone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Prednisolone	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Prednisone	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Stanozolol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Testosterone	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Triamcinolone	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction which may require dose adjustment or close monitoring
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Check for Updates

Using a saved or printed version? Click or scan to check for updates



Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Revised March 2025

Page 21 of 21

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
Vitamins/Supplements/Herbals														
African potato	◆	▲	◆	◆	◆	◆	◆	▲	◆	◆	▲	◆	◆	◆
Ayahuasca	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Beta-alanine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Branched chain amino acids	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Caffeine (anhydrous powder)	◆	◆	◆	◆	◆	▲	◆	◆	◆	◆	◆	◆	◆	◆
Calcium supplements	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cat's claw (Uncaria tomentosa)	◆	◆	◆	◆	◆	◆	◆	▲	◆	◆	▲	◆	◆	◆
Coenzyme Q10 (Ubidecarenone)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Collagen hydrolysate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Creatine monohydrate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cubeb pepper (Piper cubeba)	◆	▲	◆	◆	◆	◆	◆	▲	◆	◆	▲	◆	◆	◆
Ecdysterone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Echinacea	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Enteral feeds	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Ferrous fumarate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ferrous sulfate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Folic acid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Garlic	◆	◆	◆	◆	■	◆	■	■	◆	■	■	◆	◆	◆
Ginger (Zingiber officinale)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ginkgo biloba	◆	◆	◆	◆	■	◆	■	■	◆	■	■	◆	◆	◆
Ginseng (P ginseng, P quinquefolis)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Glucosamine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Grapefruit juice	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	▲	◆	◆	◆
Guggulsterone	◆	◆	◆	◆	■	◆	■	■	◆	■	■	◆	◆	◆
Homeopathic remedies	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Hops (Humulus lupulus)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Iodine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Iron supplements	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Liquorice (Glycyrrhiza glabra)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Malabar nut tree	◆	◆	◆	◆	■	■	■	■	◆	■	■	◆	◆	◆
Milk thistle (Silymarin)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Multivitamins	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nicotinamide (Niacinamide)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Oral nutritional supplements	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Quercetin	◆	◆	▲	◆	◆	◆	◆	■	◆	◆	■	◆	◆	◆
Red yeast rice	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
St John's wort	◆	◆	◆	◆	■	■	■	●	◆	■	■	◆	◆	◆
Turmeric (Curcumin)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Valerian	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin A (Retinol)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin B1 (Thiamine)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin B12 (Cyanocobalamin)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin B2 (Riboflavin)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin B3 (Niacin, nicotinic acid)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin B6 (Pyridoxine)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin B7 (Biotin)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin C (Ascorbic Acid)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin D2 (Ergocalciferol)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin D3 (Colecalciferol)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin E (Tocopherol)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin K (Phytomenadione)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Whey protein	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Zinc	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction which may require dose adjustment or close monitoring
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Check for Updates

Using a saved or printed version? Click or scan to check for updates

